Menopause International > Volume 15, Number 1 > Pp. 19-25

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lekander, I. Articles by Kanis, J. A Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original articles

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK

Ingrid Lekander ^* , Fredrik Borgström ^*, Oskar Ström ^*, Niklas Zethraeus  and John A Kanis 

^* i3 Innovus, Stockholm, Sweden
Stockholm School of Economics, Stockholm, Sweden
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

Correspondence: Ingrid Lekander, i3 Innovus, Klarabergsviadukten 90 Hus D, SE-111 64 Stockholm, Sweden. Email: ingrid.lekander{at}i3innovus.com
Objective. To estimate the cost-effectiveness of five-year treatment of hormone replacement therapy (HRT) compared with no treatment for women with menopausal symptoms in the UK.

Method. A Markov cohort simulation model with tunnel techniques was used to assess the cost-effectiveness of HRT in women aged 50 years. For the clinical effects of HRT we used, where possible, results taken from the Women's Health Initiative (WHI). The model had a life-time horizon with cycle lengths of one year and contained the following disease states: hip fracture, vertebral fracture, wrist fracture, breast cancer, colorectal cancer, coronary heart disease, stroke and venous thromboembolic events. An intervention was modelled by its impact on the disease risks during and after stopping treatment. The model was populated with UK-specific data on risks, mortality rates, quality-of-life weights and costs. The main outcome of the model was cost per quality-adjusted life year (QALY) gained of HRT compared with no treatment.

Results. The results indicated that it was cost-effective to treat women with menopausal symptoms with HRT in the UK. The severity of menopausal symptoms was the single most important determinant of cost-effectiveness, but HRT remained cost-effective even where symptoms were mild or effects on symptom relief were small.

Conclusions. Treatment of women with menopausal symptoms with HRT is cost-effective.

Key Words: Menopausal symptoms • HRT • Women's Health Initiative • WHI • Markov model

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. M A Shaw and S. L J Shaw Menopause, evolution and changing cultures Menopause Int, December 1, 2009; 15(4): 175 - 179. [Abstract] [Full Text] [PDF]